コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 SF3B1 wild-type tumors (including five lung adenocarcinomas).
2 omes for clinical T1aN0 and T1bN0 esophageal adenocarcinoma.
3 my in node-negative cT1a and cT1b esophageal adenocarcinoma.
4 and recurrence after resection of ampullary adenocarcinoma.
5 issue pathology images of patients with lung adenocarcinoma.
6 needed during surgical resection of prostate adenocarcinoma.
7 tage, predominantly female, non-smoking lung adenocarcinoma.
8 therapy of patients with advanced-stage lung adenocarcinoma.
9 lon but significantly downregulated in colon adenocarcinoma.
10 thologically node-negative distal esophageal adenocarcinoma.
11 tients with HER2-positive gastro-oesophageal adenocarcinoma.
12 also plays a significant role in endometrial adenocarcinoma.
13 ite of distant metastatic spread in prostate adenocarcinoma.
14 for Barrett's esophagus (BE) and esophageal adenocarcinoma.
15 e was higher in squamous cell carcinoma than adenocarcinoma.
16 targeted risk reduction programs for gastric adenocarcinoma.
17 trictures, Barrett esophagus, and esophageal adenocarcinoma.
18 n and eosin-stained pathology images in lung adenocarcinoma.
19 identifying the cell of origin for prostate adenocarcinoma.
20 n stages, from pre-neoplastic hyperplasia to adenocarcinoma.
21 ous and small cell carcinomas and weaker for adenocarcinoma.
22 e model of poorly differentiated endometrial adenocarcinoma.
23 tric metaplasia and increase risk of gastric adenocarcinoma.
24 g epithelial cells to model early-stage lung adenocarcinoma.
25 cer disease, atrophic gastritis, and gastric adenocarcinoma.
26 ns of the metalloproteinase ADAMTS12 in lung adenocarcinoma.
27 nonmetastatic and metastatic states of lung adenocarcinoma.
28 pression is associated with poor survival in adenocarcinoma.
29 t trial in subjects with metastatic prostate adenocarcinoma.
30 hest mutation frequency in BRAF gene in lung adenocarcinoma.
31 a significantly lower risk of cardia gastric adenocarcinoma.
32 sease progression that may result in gastric adenocarcinoma.
33 mone-independent pathogenesis of endometrial adenocarcinoma.
34 r-1 (ALAL-1) as frequently amplified in lung adenocarcinomas.
35 seeking to better understand and treat lung adenocarcinomas.
36 verexpressed in most human pancreatic ductal adenocarcinomas.
37 a was lower than that in other periampullary adenocarcinomas.
38 eved to be dysregulated in pancreatic ductal adenocarcinomas.
40 2002 and 2014 to 2016, compared with 10% for adenocarcinoma (18.07 to 19.84 per 100 000), ultimately
42 ry outcome was a diagnosis of distal gastric adenocarcinoma 30 days or more after detection of H pylo
43 tion rates in squamous cell carcinoma versus adenocarcinoma (65% vs 51%, P = 0.035), and a significan
44 g 29,266 lung cancer cases (including 11,273 adenocarcinomas, 7,426 squamous cell carcinoma, and 2,66
45 rolled with PDT alone were more likely to be adenocarcinoma (73% vs. 30%; P = 0.02) and those eyes we
47 s significantly longer than that of invasive adenocarcinoma (939 days [interquartile range, 588-1563
48 d of harboring high-grade dysplasia or early adenocarcinoma, a novel grasp and snare EMR technique ut
49 e confirmed a diagnosis of adenoma and early adenocarcinoma, a pathologic subtype of non-small cell l
51 f human IBD patients and in human colorectal adenocarcinoma, accounting for the epithelial YAP hypera
54 in 95% (108/113) of SCCs, and 81% (29/34) of adenocarcinoma/adenosquamous cancers on immunohistochemi
56 surgical specimen revealed a diffuse growing adenocarcinoma after an unremarkable preoperative gastro
59 mmune suppression in human pancreatic ductal adenocarcinoma and colorectal cancer by impairing the fu
60 psies from patients with metastatic prostate adenocarcinoma and CRPC-NE, we identified CRPC-NE featur
61 mmunotherapy resistance in pancreatic ductal adenocarcinoma and discuss strategies to directly augmen
62 ic mouse models of EGFR(L858R) -induced lung adenocarcinoma and found that it is mediated largely thr
63 sms are resectable stage I pancreatic ductal adenocarcinoma and high-risk precursor neoplasms, such a
64 aled loss of Mst1/2 promotes aggressive lung adenocarcinoma and large-scale proteomic analysis reveal
66 an indicator of cancer burden in esophageal adenocarcinoma and may identify patients who may most be
67 ectomy for remote left upper lobe stage IIIA adenocarcinoma and prior bilateral breast implantation f
68 how that PINCH-1 is highly expressed in lung adenocarcinoma and promotes proline synthesis through re
69 sed with a new right upper lobe stage I lung adenocarcinoma and underwent video-assisted thoracoscopi
71 verall survival in breast, lung, and stomach adenocarcinomas and increased relapse and distant metast
72 tures of cells to be increased in colorectal adenocarcinomas and inversely correlated with expression
73 KRAS(G12C), a mutation found in ~13% of lung adenocarcinomas and, at a lower frequency, in other canc
74 rt (n = 633), younger age, central location, adenocarcinoma, and higher positron emission tomography-
75 ding colon, breast, prostate, pancreas, lung adenocarcinoma, and squamous cell carcinoma) for the fre
76 f somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and
77 the unique metabolic properties of prostate adenocarcinoma are likely to stem from the distinct meta
80 ents were highly discriminant for esophageal adenocarcinoma both in discovery (AUC = 0.97) and valida
81 for tyrosine kinase inhibitors (TKI) in lung adenocarcinoma, but acquired resistance to TKIs inevitab
82 d 2, which are silenced in pancreatic ductal adenocarcinoma, but upregulated with P-AscH(-) treatment
83 n a subset of surgically resected human lung adenocarcinomas by multispectral imaging, which provided
84 -obtained BRJ to human epithelial colorectal adenocarcinoma (Caco-2) and human non-malignant intestin
85 etting, P-AR for locally advanced pancreatic adenocarcinoma can be performed safely with limited mort
88 d patient survival times from 456 colorectal adenocarcinoma cases, and a separate set of 594 samples
89 ary cells (fibroblasts) and against a breast adenocarcinoma cell line (MCF7) in hypoxic environment.
91 crucial role of hMATE1 was validated in lung adenocarcinoma cells (A549), which expresses high levels
97 s from these mice were poorly differentiated adenocarcinoma, characterized by extensive epithelial-me
100 mpared with pure lung adenocarcinoma (LUAD), adenocarcinoma component of PSC showed lower EGFR incide
101 ological citrate secretion, whereas prostate adenocarcinoma consumes citrate to power oxidative phosp
102 GEMMs) of KRAS-dependent pancreatic and lung adenocarcinomas converts preneoplastic lesions into inva
103 like transdifferentiation of prostate cancer adenocarcinomas correlates with serum levels of chromogr
104 ocrine differentiation of Pten null prostate adenocarcinoma, corroborates that the lineage status of
107 letion of DeltaNp63 inhibits primary mammary adenocarcinoma development, oscillatory expression of De
108 se III trial, patients with stage IIIB or IV adenocarcinoma diagnosed > 6 months before study entry a
109 accelerated pace at which pancreatic ductal adenocarcinoma drugs are achieving successful clinical o
111 and neck cancer (HNC; n = 2,453), esophageal adenocarcinoma (EA; n = 855), esophageal squamous cell c
114 in patients with locally advanced esophageal adenocarcinoma (EAC) treated with neoadjuvant chemoradio
115 ith high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), from 1992 through 2015, and perfor
121 can model non-small cell lung cancer (NSCLC) adenocarcinomas, enabling treatment studies to validate
122 ified and less well-characterized pathway of adenocarcinoma escape from suppressive anticancer therap
123 atic CRPC clinical samples + PDX models with adenocarcinoma features (CRPC-adeno) vs those with neuro
125 can objectively identify invasive esophageal adenocarcinoma from a number of premalignant tissues and
126 nalysis of circulating MDSCs from 20 gastric adenocarcinoma (GAC) patients found that >=80% ARG1-expr
127 h repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their M
128 resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropr
130 lower lobe cancer had a lower proportion of adenocarcinoma histology and epidermal growth factor rec
131 clinically as transformation from a prostate adenocarcinoma histology to a castration-resistant neuro
132 Barrett's oesophagus prevents progression to adenocarcinoma; however, the optimal diagnostic strategy
133 n mucosal healing risk of future small bowel adenocarcinoma (HR, 0.18; 95% CI, 0.02-1.61), although t
134 atic progression; SW480 derived from primary adenocarcinoma, HT29 from a more advanced primary tumor
135 assessed by cytotoxicity assays performed in adenocarcinoma human alveolar basal epithelial (A549) an
137 ressive, immunocompetent mouse model of lung adenocarcinoma improves long-term survival and cisplatin
138 nderwent pancreatoduodenectomy for ampullary adenocarcinoma in 9 European tertiary referral centers b
139 cinoid tumor IRs increased more steeply than adenocarcinoma in all age groups, thus affecting the con
140 erall, there was 1 extra case of small bowel adenocarcinoma in every 2944 patients with CD followed f
142 rough 2015 to estimate incidences of gastric adenocarcinoma in specific anatomic sites for non-Hispan
144 al crypts and accelerates CRC progression to adenocarcinoma in the milieu of APC(Delta14/+), a phenom
145 eefold) increase in atypical hyperplasia and adenocarcinomas in the small and large intestines; howev
147 precise, contemporary information on gastric adenocarcinoma incidence in specific anatomic sites for
148 lary mucosal neoplasms and pancreatic ductal adenocarcinoma including the characterization of their R
149 was subsequently reported in multiple other adenocarcinomas, including prostate cancer in the presen
150 thologically node-negative distal esophageal adenocarcinoma, independent of presence of high risk cha
151 d 50 to 80 years with biopsy-proven prostate adenocarcinoma (International Society of Urological Path
152 ndrome develop a rare "medullary" variant of adenocarcinoma, intraductal papillary mucinous tumors ar
155 ggest that the metastatic cell state in lung adenocarcinoma is associated with a specifically altered
157 for germline BRCA-mutated pancreatic ductal adenocarcinoma is expected to be approved soon in the ma
159 lead to the development of pancreatic ductal adenocarcinoma, its progression, and the interplay betwe
164 e genomic and transcriptomic dataset of lung adenocarcinoma (LUAD) in individuals of East Asian ances
170 Purpose To test whether the growth of lung adenocarcinomas manifesting as subsolid nodules at chest
171 bution of hepatic metastases from colorectal adenocarcinoma may not be associated with the primary tu
172 on analysis, screening for noncardia gastric adenocarcinoma might be cost-effective for non-White ind
173 ostate-specific PTEN-/- (KO) mouse prostatic adenocarcinoma model through DNA methyl-Seq and RNA-Seq
174 d to characterize a novel aggregated 3D lung adenocarcinoma model, developed by the group to mimic th
176 erone did not mitigate poorly differentiated adenocarcinoma, nor did it affect adnexal metastasis.
181 alysis for somatic L1 insertions, we studied adenocarcinomas of colon, pancreas, and stomach, and fou
182 impact of the primary location of colorectal adenocarcinoma on the lobar distribution of its hepatic
183 are associated with a higher risk of gastric adenocarcinoma or peptic ulcer disease than cag PAI-nega
184 primary tumor in patients with biopsy-proven adenocarcinoma or squamous cell carcinoma of the esophag
185 ile reduced FEV(1)/FVC increases the risk of adenocarcinoma (OR = 1.17, 1.01-1.35) and lung cancer in
186 lternative treatment to chemotherapy in lung adenocarcinoma osimertinib-treated patients after diseas
189 % vs. 26.7% non-mucinous, and 26.9% mucinous adenocarcinoma, P < 0.001), removing < 12 lymph nodes (3
193 38alpha correlate with poor survival in lung adenocarcinoma patients, and that genetic or chemical in
195 ant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes
198 ed time for development of pancreatic ductal adenocarcinoma (PDA) is more than 20 years, PDAs are usu
200 d are cystic precursors to pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA), resp
203 non-invasive detection of pancreatic ductal adenocarcinoma (PDAC) by 5-hydroxymethylcytosine (5hmC)
209 outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) have lagged behind advances made i
220 osis and dismal prognosis, pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating sol
226 In the well-established pancreatic ductal adenocarcinoma (PDAC) mouse model, expression of the ace
232 , neoantigen expression in pancreatic ductal adenocarcinoma (PDAC) results in exacerbation of a fibro
234 lly advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) treated with FOLFIRINOX, and to in
235 to demonstrate that mouse pancreatic ductal adenocarcinoma (PDAC) tumors and human PDAC cell lines r
236 ancreatic duct (>3 mm) and pancreatic ductal adenocarcinoma (PDAC) were associated with a better TO r
237 xpand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass spectrom
239 usceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A, encoding Lysine-spec
240 modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contribu
251 ur in approximately 10% of pancreatic ductal adenocarcinomas (PDAC), but whether these mutations conf
252 Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in patients with a germl
254 show that ILC2s infiltrate pancreatic ductal adenocarcinomas (PDACs) to activate tissue-specific tumo
256 ssessing the invasiveness of individual lung adenocarcinomas presenting as subsolid nodules on comput
257 ctional variant rs17079281C>T decreased lung adenocarcinoma risk by creating an YY1-binding site to s
260 ssion and poor outcome in patients with lung adenocarcinoma specifically harboring KRAS mutations.
261 trend <= 0.01) with increasing risks of lung adenocarcinoma, squamous cell carcinoma, and small cell
262 h lymphovascular space invasion, IA2, or IB1 adenocarcinoma, squamous cell carcinoma, or adenosquamou
263 the B3 domain of human CEACAM5 in colorectal adenocarcinomas; structural studies indicated that these
264 with other main risk factors for esophageal adenocarcinoma, such as older age, male sex, and obesity
265 h CRPC-NE compared with castration-resistant adenocarcinoma, supporting greater intraindividual genom
266 t uPAR extend the survival of mice with lung adenocarcinoma that are treated with a senescence-induci
267 0 (n = 2545) and T1bN0 (n = 1281) esophageal adenocarcinoma that received either ER (cT1a, n = 1581;
268 thods were applied for a model of esophageal adenocarcinoma that was previously calibrated to U.S. ca
269 , analysis of histologic subtypes, including adenocarcinoma (the focus of CRC screening and diagnosti
270 RKD1 were reduced in human pancreatic ductal adenocarcinoma tissues compared with nontumor tissues.
271 ious cancers, ranging from prostate and lung adenocarcinoma to melanoma and basal cell carcinoma.
272 cancer - the histological transformation of adenocarcinomas to aggressive neuroendocrine derivatives
274 ng non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been proposed a
275 glycolysis in three human pancreatic ductal adenocarcinoma tumor xenografts with differing physiolog
276 ate that, within colon and pancreatic ductal adenocarcinoma tumors, efficient stromagenesis relies on
277 ighly aggressive subset of pancreatic ductal adenocarcinomas undergo trans-differentiation into the s
280 chemistry in a series of 99 human pancreatic adenocarcinomas versus 48 normal pancreatic tissues (P =
281 (0.06%) received a diagnosis of small bowel adenocarcinoma vs 45 reference individuals (0.02%), 7 pa
282 ars and older, the risk of noncardia gastric adenocarcinoma was 1.8-fold (95% CI, 1.37-2.31) to 7.3-f
284 SFPR1 gene and SFRP1 expression in ampullary adenocarcinoma was lower than that in other periampullar
285 icroarray analysis of SFRP1 in periampullary adenocarcinoma was obtained from the Gene Expression Omn
286 e median volume doubling time of noninvasive adenocarcinoma was significantly longer than that of inv
287 from patients affected by pancreatic ductal adenocarcinoma, was observed, pointing to this class of
288 a genetically-engineered mouse model of lung adenocarcinoma, we show that the deletion of only one hi
291 d KB cell line, a cellular model of cervical adenocarcinoma, where FKBP51 is highly overexpressed.
292 st generated a KRAS-specific SigMap for lung adenocarcinoma, which recapitulated published KRAS biolo
294 ighty-six patients diagnosed with colorectal adenocarcinoma, who had hepatic metastases on the initia
295 year-old female patient with metastatic lung adenocarcinoma, who harbored KIF5B-RET fusion and had hi
297 ositive, PD-L1-unselected gastro-oesophageal adenocarcinoma, with an Eastern Cooperative Oncology Gro
298 008 and September 2011, patients with rectal adenocarcinoma within 12 cm from the anal verge, T3/4 an
300 r the growth of both cultured cells and lung adenocarcinoma xenografts, while a subset had clinically